Does Rallies show Form 4 insider transactions for SNTI?

Yes. Rallies tracks SNTI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SNTI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SNTI. It does not provide personalized investment advice.

SNTI (Senti Biosciences Holdings, Inc. Common Stock) Stock Analysis - Insider Trades

Senti Biosciences Holdings, Inc. Common Stock (SNTI) is a publicly traded Healthcare sector company. As of May 21, 2026, SNTI trades at $0.95 with a market cap of $29.28M and a P/E ratio of -0.35. SNTI moved +7.91% today. Year to date, SNTI is -13.27%; over the trailing twelve months it is -69.38%. Its 52-week range spans $0.77 to $16.94. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces SNTI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SNTI stock inside the company?

Recent SNTI insider activity includes Lu Timothy K sold 545, Rajangam Kanya sold 182, Lu Timothy K sold 3.92K, and Rajangam Kanya sold 1.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SNTI Key Metrics

Key financial metrics for SNTI
Metric	Value
Price	$0.95
Market Cap	$29.28M
P/E Ratio	-0.35
EPS	$-2.73
Dividend Yield	0.00%
52-Week High	$16.94
52-Week Low	$0.77
Volume	81
Avg Volume	0
Revenue (TTM)	$22.00K
Net Income	$-61.44M
Gross Margin	0.00%

Recent SNTI Insider Trades

Lu Timothy K sold 545 (~$2.38K) on Feb 6, 2025.
Rajangam Kanya sold 182 (~$795.34) on Feb 6, 2025.
Lu Timothy K sold 3.92K (~$15.96K) on Feb 4, 2025.
Rajangam Kanya sold 1.30K (~$5.28K) on Feb 4, 2025.

Latest SNTI News

Senti Biosciences Secures $40M Financing, Advances SENTI-202 Pivotal AML Trial — May 14, 2026
Senti Biosciences Unveils 60+ NOT-Gated CAR Designs with Improved Tumor Precision — Apr 1, 2026
Senti Biosciences Reports $61.4M 2025 Net Loss, Positive AML Data with RMAT — Mar 27, 2026
Senti Biosciences to Showcase Phase I SENTI-202 AML Safety and Activity Data — Mar 23, 2026
Senti Bio Showcases Phase 1 Logic-Gated SENTI-202 CAR-NK Therapy with FDA Orphan & RMAT Designations — Feb 20, 2026

SNTI Analyst Consensus

1 analysts cover SNTI: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.

Common questions about SNTI

Who is trading SNTI stock inside the company?: Recent SNTI insider activity includes Lu Timothy K sold 545, Rajangam Kanya sold 182, Lu Timothy K sold 3.92K, and Rajangam Kanya sold 1.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SNTI?: Yes. Rallies tracks SNTI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SNTI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SNTI. It does not provide personalized investment advice.